• Since the earliest clinical description of thyrotoxicosis by Parry, the frequent involvement of the cardiovascular system in this disease has been noted. 1 In addition to other manifestations of cardiovascular involvement, ventricular hypertrophy has been found occasionally in patients with hyperthyroidism. However, the factors responsible for this hypertrophy have been the subject of controversy. Some authors have felt that cardiac hypertrophy occurred only when there was co-existent organic heart disease, esr ' 2 ' 3 while others have believed that hypertrophy might result solely from excessive thyroid hormone activity. 4 Subsequent work has shown clearly that a substantial increase in heart weight can be obtained by treating normal experimental animals with thyroid hormone/'" 8 Furthermore, although metabolic balance studies have demonstrated net protein catabolism after treatment with large amounts of thyroid hormone, 9 ' 10 small amounts of hormone have been found to stimulate protein synthesis in various tissues, including the heart, both in vivo and in vitro. 11 The mechanism by which this stimulation of protein synthesis is accomplished is uncertain. 12 Dr. Aroesty was a Trainee and Postdoctoral Fellow of the U. S. Public Health Service.
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Accepted for publication October 11, 1965. Many investigators have felt that certain cardiac and peripheral circulatory manifestations of thyrotoxicosis are due to increased physiological activity of the catecholamines in this disorder. 15 ' 10 Reserpine has been used, therefore, in the treatment of thyrotoxic patients with tremor, tachycardia, and increased cardiac output. Whether the hypermetabolism of thyrotoxic patients is catecholamine-mediated and whether reserpine reverses this hypermetabolism remains controversial. 15 " 21 Hoch, in his extensive review, concluded that the hypermetabolism of thyrotoxicosis was not catecholamine-mediated but that most of the peripheral circulatory changes were induced by excessive catecholamine activity. 22 The role that catecholamines may play in the development of thyroxine-induced hypertrophy is still uncertain and needs further study. Coronary blood flow, myocardial oxygen consumption, total cardiac output and presumably cardiac work are all increased in thyrotoxicosis. These factors, singly, or in combination, might lead to cardiac hypertrophy.
The present study was undertaken to determine whether the cardiac hypertrophy induced by thyroxine in experimental animals is a result of the circulatory changes accompanying thyrotoxicosis or, at least in part, the result of a hormonal effect on myocardial growth.
THYROXINE-INDUCED CARDIAC HYPERTROPHY
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Company) containing 2.5 mg reserpine per ml. L-leucine-1-C* was obtained from the New England Nuclear Corporation.
EXPERIMENT 1
Several series of animals were divided into groups of 15 and placed in stainless steel cages. All animals were housed in a single cage rack under comparable environmental conditions. To produce thyrotoxicosis thyroxine was fed to some animals as pulverized Synthroid tablets. The equivalent of 22 mg of sodium Z-thyroxine was mixed into 3.5 kg of meal and the mixture was placed in hanging food bins. Despite large losses of food because of spillage, the animals received sufficient thyroxine to render them thyrotoxic. Although it was not possible to measure food intake precisely, the rate of disappearance of food from the bins was measured.
The body weights of control and thyroxine fed animals were determined at intervals for approximately six weeks. Using a separate series of mice, at predetermined intervals of 3, 6, 13, 20, 27, 34 and 41 days from the start of the experiment, after individual weighing on a Harvard trip balance, five animals were sacrificed from the control group and five from the group fed thyroxine. The excised, blotted hearts were weighed to the nearest mg on a precision tissue balance, and the wet heart weight:body weight ratios were calculated. A portion of the ventricular myocardium was dried to constant weight at 120°C, and dry heart weight:wet heart weight ratios were then determined. A block of left ventricular tissue, cut from the apex of the heart, was fixed in formalin for five days for microscopic estimate of fiber size and concentration of nuclei per microscopic field. With routine paraffin techniques, sections 7 JJL thick were prepared and then stained with hematoxylin and eosin. Fiber size was estimated in an oil immersion field with an ocular micrometer by measuring the smallest diameter of those fibers cut lengthwise, in which a nucleus was visible. One thousand fibers were so measured from each block of tissue sectioned. Counts of nuclei/field were made by oil immersion lens for confirmation of these results.
The results of this experiment were used to plot changes in growth pattern and changes in heart size induced by thyroxine as a function of time, and also, to determine whether the changes in heart weight were due to an increase in muscle mass or to a change in water content of the myocardium. Simplified apparatus for making comparative measurements of oxygen consumption in individual mice. For details see text.
meal to which sodium Z-thyroxine had been added; these animals received ordinary drinking water. Group C was fed ordinary laboratory meal, but received drinking water containing reserpine.* Group D was fed thyroxine and received reserpine in the drinking water. At intervals of 3, 6, 10 and 14 days after beginning this study period, heart rate and oxygen consumption were measured in each animal.
Resting heart rates were recorded in unanesthetized and unrestrained animals. Electrocardiogram cables were connected to the loose skin of the animals' extremities, using alligator clips. Tracings were recorded at a paper speed of 50 mm/sec on a direct-writing Sanborn electrocardiograph. After a short period of observation, the animals did not seem to be disturbed by the clips or by the weight of the cables.
'Reserpine was added to the drinking water in a concentration of 0.5 mg per 100 ml, and the solutions were changed at intervals of two to three days. The animals could drink ad libitum in all experiments. Their intake of reserpine was approximately 0.05 mg/mouse/day. The apparatus for making comparative measurements of oxygen consumption in these animals ( fig. 1 ) consisted of a 500 ml Erlenmeyer flask with CO 2 absorber (Edison Baralyme) placed beneath a mesh screen on the bottom of the flask. Mice were placed in the chamber singly and were allowed approximately 20 minutes to accommodate to the environment. The flask containing room air was then sealed with a large rubber stopper, through the center of which an outlet tube led to a 1 ml graduated pipette, suspended with its tip in a beaker of water. As the animal consumed oxygen, the level of water rose progressively in the pipette. The rate of water displacement was determined with a stop watch by recording the time taken for the meniscus to travel 0.5 ml. Serial readings were recorded for each animal until five comparable measurements were obtained, indicating that a steady state had been reached. The mean of these five values was used to determine the oxygen consumption/100 g body weight for each animal on a given day of study. All measurements were made at ambient temperature, and the animals of all the test groups were studied in the same room over a five-to six-hour period on any given day.
At the end of the study, a number of the animals were anesthetized with an allobarbitalurethane-monoethylurea mixture,* and arterial blood pressure also was measured. Measurements of heart rate and blood pressure in anesthetized animals were made as described elsewhere. 23 A cannula placed in the carotid artery was connected to a P23AA Statham transducer and blood pressure and heart rate were recorded on a direct-writing Grass model P5 polygraph. The hearts of all animals were removed after 14 days. Cardiac wet weight, and in a smaller number dry weight and myocardial fiber size, were estimated. This study was used to assess the relationship between changes in heart size and the effects of thyroxine and reserpine on oxygen consumption and the general circulation.
EXPERIMENT 3
In separate experiments mice were divided into groups of 15 as described in experiment 1. Each mouse was then injected with either 0.4 ml of 0.5% chlorobutanol (control group) or with 0.4 ml of sodium Z-thyroxinet in 0.5% chlorobutanol (treated group). After 24 hours, these injections were repeated. Forty-eight hours after the beginning of the study, heart rate and oxygen consumption were determined in each animal, and in certain animals carotid arterial blood pressure also *Dial-urethane, Ciba, 0.6 ml/kg. fEquivalent to 40 ng Na-i-thyroxine. was measured. Fifteen control animals and 15 animals that had received Z-thyroxine subcutaneously for 48 hours were given 1.25 microcuries each of lAeucine-1-C" 1 . One hour later the animals were sacrificed, their hearts removed and homogenized, and the specific radioactivity of total myocardial protein was determined as follows: Each heart was homogenized in 5 ml of 0.25 M sucrose in a Potter-Elvejhem ground glass homogenizer. An equal volume of 10% trichloroacetic acid was added to precipitate protein.
The precipitates were washed and the protein weighed and counted by liquid scintillation spectrometry as described elsewhere. 24 
Results
PRODUCTION OF THYROTOXICOSIS
The growth curves of control mice and of mice fed synthetic Z-thyroxine for six weeks are shown in figure 2 . After approximately three weeks, in spite of a normal or increased food intake, mice fed thyroxine no longer gained weight, while the growth rate of control mice was approximately linear throughout the sixweek study period. In addition, oxygen consumption was distinctly greater in thyroxinefed mice than in controls (table 1 ). An effect on oxygen consumption was clearly apparent after two weeks had elapsed and in some instances was detected as early as 7 to 10 days after thyroxine feeding had begun. Within two Crowth curves of control mice and of mice fed synthetic l-thyroxine for approximately six weeks. Each point represents the mean weight of 15 mice at the time specified with a standard error of less than 10% of the mean value in every instance. weeks, the circulatory manifestations of thyrotoxicosis also became apparent. These included tachycardia and also an increase in the product of heart rate and arterial pulse pressure (10,980 ±1345 to 15,670 ±1695*), this difference being significant (P < 0.05).
THYROXINE-INDUCED CARDIAC HYPERTROPHY
The effect of oral thyroxine on the ratio of wet heart weight to body weight as a function of time is shown in figure 3 . By ten days after the beginning of the study period, this ratio increased significantly, and the increase persisted for the full six weeks of the experiment. This increment was due to an absolute increase in heart weight, rather than to decreasing body weight, as indicated by the results shown in table 2. Furthermore, the increase in heart weight was not due to an increased water content of the myocardium, since dry heart weight:wet heart weight ratios were virtually identical in control mice and in those fed thyroxine. A statistically significant increment in myocardial fiber diameter in mice fed thyroxine became apparent *NIean ± standard error of the mean. Wet heart weight:body weight ratios as a function of time in control mice and in mice fed synthetic l-thyroxine for approximately six weeks. Each point represents a mean value for five animals, with a standard error of less than 10% of the mean value in each case. when absolute heart weight was found to be unequivocally increased (table 2) .
EFFECTS OF RESERPINE ON THE CIRCULATORY CHANGES, INCREASED OXYGEN CONSUMPTION, AND THE MYOCARDIAL HYPERTROPHY PRODUCED BY FEEDING l-THYROXINE
Orally administered reserpine produced bradycardia, and oral thyroxine produced tachycardia, in control mice. When mice re- ceived thyroxine and reserpine concurrently, their heart rates were no greater than those of control animals, yet their heart rates were definitely greater than those fed reserpine alone. Reserpine had no effect on the increment in oxygen consumption produced by thyroxine. These results are all shown in table 3. It was impossible to assess the effect of reserpine on the product of heart rate and arterial pulse pressure in the group fed both thyroxine and reserpine. Although the heart rates of animals fed both thyroxine and reserpine were not greater than those of control animals in the waking state, they often developed very rapid heart rates ;^v hen anesthetized. In many .instances their heart rates were higher than those of animals receiving thyroxine alone. Thus, although arterial pulse pressure was not increased in the mice fed both thyroxine and reserpine, in comparison to the thyroxine-fed group (fig. 4) , the prod- Representative carotid arterial pressure tracings at the end of a two-week study period in a control mouse, and in mice fed reserpine, thyroxine, and a combination of thyroxine and reserpine, respectively. Note the bradycardia in the animal treated with reserpine only, the tachycardia and wide pulse pressure in the thyroxine-fed animal, and the tachycardia without a widened pulse pressure in the animal on combined treatment.
uct (heart rate times pulse pressure) was almost as high as in thyroxine-fed animals. When mice fed thyroxine and those fed both thyroxine and reserpine were matched according to comparable heart rate, the former group always showed a higher arterial pulse pressure. Thus the circulatory changes produced by thyroxine treatment were not seen in animals fed both thyroxine and reserpine, when these groups were compared to the control animals of Group A. Yet the increases in heart size and in true muscle mass in animals fed both reserpine and thyroxine were as great as in those animals fed thyroxine alone (table 4) .
EFFECTS OF SUBCUTANEOUS THYROXINE ON THE CIRCULATION, ON OXYGEN CONSUMPTION AND ON MYOCARDIAL PROTEIN SYNTHESIS AS A FUNCTION OF TIME
The results of the experiments after subcutaneous injection of synthetic Z-thyroxine are shown in figure 5 . Although thyroxine failed to produce either tachycardia or a change in the product of pulse pressure and heart rate within the first 48 hours of treatment, its administration did increase oxygen consumption. In addition, the rate of incorporation of C H leucine into cardiac protein was significantly greater in those animals treated with thyroxine. This effect of thyroxine on myocardial protein synthesis in Circulation Research, Vol. XVIII, April 1966 vivo was not blocked by pretreatment of the animals with oral reserpine (table 5) .
Discussion
The thyroxine-fed mice used in these studies were clearly thyrotoxic. They failed to gain weight properly in spite of adequate food intake, and their oxygen consumption was increased. They developed tachycardia and an increased product of heart rate times arterial pulse pressure. In association with these manifestations of thyrotoxicosis, the animals developed cardiac hypertrophy, the degree of which was similar to that reported by other investigators. 0 '" The findings of similar dry heart weight:wet heart weight ratios in these animals compared to those in control animals, and the increased fiber size* without apparent edema of muscle fibers suggest that the increase in heart weight was due to an increase in muscle mass. In addition, the observation that thyroxine stimulated incorporation of C" 1 labelled leucine into myocardial protein was further evidence that ah increase *Values for myocardial fiber size found in these experiments agree closely with those reported by others. 2 Effects of 2 injections of synthetic l-thyroxine at 24-hour intervals on heart rate, on the product of heart rate times puhe pressure in anesthetized animals, on oxygen consumption, and on rate of synthesis of cardiac protein. In each instance, the mean value is represented by the top of the open bar, and the standard errors of the mean are shown. In 10 animals from each group heart rate and oxygen consumption were studied, and in 6 control and 7 thyroxineinjected animals carotid blood pressure was measured. Isotope was administered to 16 controls and to 16 animals injected with thyroxine. After 48 hours there was no significant effect of thyroxine on either heart rate or on the product of heart rate times pulse pressure (P > 0.05). Yet, both oxygen consumption and the incorporation of leucine-l-C'4 into myocardial protein were increased significantly in thyroxine treated (T) vs. control (C) animah (P < 0.01). in true muscle mass was induced by the hormone.
Reserpine produced resting bradycardia and in thyroxine-fed animals brought the heart rates into the range seen in normal control animals. It should be noted that the heart rates in animals fed both thyroxine and reserpine were greater than in those animals fed reserpine alone. In fact, the increment in heart rate induced by thyroxine in reserpinized animals may have been greater than the increase in heart rate produced by the hormone in controls. Whether the reserpinized animal is more sensitive to the hemodynamic effects of thyroxine merits further investigation. However, in the context of the present study, the important finding is that the heart rates in mice fed both thyroxine and reserpine were no greater than those of control ani-mals. Yet, reserpine failed to inhibit the cardiac hypertrophy induced by thyroxine. These results suggest that thyroxine has an effect on heart growth that may be independent of the circulatory changes that occur in thyrotoxicosis.
Further support for the concept that thyroxine has effects on heart growth, independent of its effects on the circulation, has been derived from a comparison of the time required for thyroxine to affect cardiac protein synthesis, compared to the time required for thyroxine to produce observable changes in the circulation. There was an unequivocal hormonal effect on incorporation of leucine-1-C" 1 into total myocardial protein at a time when thyroxine had a statistically insignificant effect on either heart rate or the product of heart rate times arterial pulse pressure. It is recognized that the mean values of both heart rate and the product, heart rate times arterial pulse pressure, were greater in thyroxine-injected animals at 48 hours, and that the lack of statistical significance may be due largely to wide scatter of the values about the means. This may reflect an early circulatory effect of thyroxine in a few of the animals, because by 72 or 96 hours, obvious circulatory changes have been observed. Yet, at a time when only minimal and insignificant circulatory changes were apparent, very definite and striking changes in myocardial protein synthesis had occurred.
It seems likely therefore that the effect of thyroxine on myocardial protein synthesis is largely a result of its effect on cardiac metabolism. It is not possible to say from these studies whether the effect of thyroxine on heart growth in these animals is a direct hormonal action, or is brought about through some intermediate process or product that results from thyroxine treatment. In all likelihood, the effect depends at least on a permissive action of growth hormone. 20 Our data differ in certain respects from those reported by some investigators. In the present study reserpine failed to reverse the increase in oxygen consumption caused by thyroxine. Species differences, dosage factors and variations in technique may explain the apparent divergence in results. In addition, certain investigators have found that parenteral thyroid hormone increased heart rate with a lag period of considerably less than 48 hours. eg>27 However, these early effects on the circulation have been observed only in myxedematous animals.
The role of the catecholamines in the production of thyroxine-induced cardiac hypertrophy is not entirely clear. Certain observations suggest that the catecholamines may not be involved in this process. It is difficult to produce cardiac hypertrophy in experimental animals by chronic administration of catecholamines alone. 28 Furthermore, in the present study, reserpine failed to suppress thyroxine-induced cardiac hypertrophy. It should be pointed out that prolonged treatment of experimental animals with thyroxine leads to destructive myocardial lesions that are similar to those produced by repeated administration of epinephrine or norepinephrine. 29 -30 The view that thyroxine may have direct effects on tissue growth and protein synthesis is not new. Although thyrotoxicosis is associated with a net negative nitrogen balance and overall tissue catabolism, experiments both in vivo and in vitro have shown that thyroxine in small amounts can stimulate protein synthesis in many tissues including the heart. 11 It is clear from the present study and work of others that experimental thyrotoxicosis is associated with a definite increase rather than a decrease in heart mass. Thus, the effect on the heart of thyroid over-activity is not one of net catabolism. This does not exclude the presence of greater turnover of heart muscle protein in thyrotoxicosis, but indicates only that the net effect observed is one of excessive tissue growth.
Summary
Thyroxine was administered to mice to determine whether the cardiac hypertrophy which accompanies experimental thyrotoxicosis is a result of circulatory changes produced by thyroxine, or the result of a hormonal effect on myocardial growth. When mice were fed both reserpine and thyroxine they developed as much cardiac hypertrophy as those fed thyroxine alone, although the circulatory changes associated with thyrotoxicosis were greatly reduced by reserpine treatment. In addition, when mice were injected with synthetic J-thyroxine, the rate of cardiac protein synthesis was increased before any definite circulatory changes were observed.
The results suggest an effect of thyroid hormone on cardiac protein synthesis that is independent of the effects of the hormone on the general circulation.
